Sab Biotherapeutics, Inc. ( (SABS) ) has released its Q2 earnings. Here is a breakdown of the information Sab Biotherapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. In its latest earnings report, SAB Biotherapeutics disclosed a net loss of $15.3 million for the first half of 2025, compared to a $12.4 million loss in the same period last year, with no revenue generated during this time. The company’s operating expenses were primarily driven by research and development costs, which totaled $14.7 million, and general and administrative expenses of $5.9 million. Despite the financial losses, the company successfully raised approximately $175 million through a private placement offering to fund its ongoing research and development activities, including the Phase 2b SAFEGUARD study of its lead candidate, SAB-142. Looking ahead, SAB Biotherapeutics anticipates continued financial challenges as it progresses its product candidates through development and regulatory approval processes, with management actively seeking additional funding to support its long-term strategic goals.